Neuroleptic Malignant Syndrome Concurrent with COVID-19 Infection: A Case Report COVID-19 Hastasında Nöroleptik Malin Sendrom: Bir Olgu Sunumu

Gökçen O., Akkuş M.

Turk Psikiyatri Dergisi, vol.35, no.1, pp.75-77, 2024 (SSCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 1
  • Publication Date: 2024
  • Doi Number: 10.5080/u27125
  • Journal Name: Turk Psikiyatri Dergisi
  • Journal Indexes: Social Sciences Citation Index (SSCI), Scopus, Central & Eastern European Academic Source (CEEAS), MEDLINE, Psycinfo
  • Page Numbers: pp.75-77
  • Keywords: Antipsikotik, Antipsychotic, COVID-19, COVID-19, Enfeksiyon, Infection, Neuroleptic Malignant Syndrome, Nöroleptik Malign Sendrom, Risperidon, Risperidone
  • Kütahya Health Sciences University Affiliated: Yes


Neuroleptic malignant syndrome (NMS), which most often occurs after the use of antipsychotics, is a rare but life-threatening condition. In this article, a 56-year-old male patient with a diagnosis of bipolar affective disorder (BPD) who developed NMS after a COVID-19 infection will be presented. The patient had been brought to the emergency room with high fever, fatigue, and slowness of movements that had been going on for two days. The examination revealed tachycardia, tachypnea, lethargy and rigidity. Upon further investigation the COVID-19 test came out positive and the serum levels of creatine kinase were considerably high. He was admitted to the psychiatric ward with diagnoses of COVID-19 infection and NMS. COVID-19 infection might have been a risk factor for NMS in this patient. Especially in patients who are taking antipsychotic drugs, if COVID-19 is present, the risk of NMS should be taken into consideration.